Lancemaside A from Codonopsis lanceolata prevents hypertension by inhibiting NADPH oxidase 2-mediated MAPK signalling and improving NO bioavailability in rats

You Kyoung Shin, A. Young Han, Yu Shan Hsieh, Soonho Kwon, Jinhye Kim, Kwang Won Lee, Geun Hee Seol

Research output: Contribution to journalArticle

Abstract

Objectives: This study investigated whether lancemaside A (LMA) can prevent hypertension and assessed the mechanisms of action of LMA in rats. Methods: Hypertension was induced by chronic immobilization stress and nicotine administration. Hypertensive vehicle rats were treated with LMA (1, 20, or 40 mg/kg) or nifedipine (10 mg/kg) as a positive control daily for 3 weeks. Key findings: In hypertensive vehicle rats, LMA dose-dependently reduced systolic blood pressure. LMA doses of 20 and 40 mg/kg reduced the aortic expression of nicotinamide adenine dinucleotide phosphate oxidase (NOX)2 (both P < 0.01), and 40 mg/kg LMA reduced serum malondialdehyde (P < 0.01). Serum nitrite levels were significantly higher in LMA treated rats than in hypertensive vehicle rats, with LMA doses of 20 and 40 mg/kg reducing the expression of endothelial nitric oxide synthase in rat aortas (P < 0.001 and P < 0.01, respectively). LMA also reduced the aortic levels of nuclear factor kappa B and the activation of the three isoforms of mitogen-activated protein kinase (MAPK). Conclusions: Lancemaside A prevents hypertension in rats by inhibiting the activation of MAPK signalling and the impairment in nitric oxide bioavailability due to NOX2-mediated oxidative stress. Thus, LMA may act as a preventive agent for hypertension.

Original languageEnglish
Pages (from-to)1458-1468
Number of pages11
JournalJournal of Pharmacy and Pharmacology
Volume71
Issue number9
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Codonopsis
NADPH Oxidase
Mitogen-Activated Protein Kinase 1
Biological Availability
Hypertension
Mitogen-Activated Protein Kinases
lancemaside A
Blood Pressure
NF-kappa B
Nifedipine
Nitrites
Malondialdehyde
Serum
NADP
Nicotine
Immobilization

Keywords

  • antihypertension
  • lancemaside A
  • MAPK
  • NADPH oxidase
  • NO bioavailability

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Lancemaside A from Codonopsis lanceolata prevents hypertension by inhibiting NADPH oxidase 2-mediated MAPK signalling and improving NO bioavailability in rats. / Shin, You Kyoung; Han, A. Young; Hsieh, Yu Shan; Kwon, Soonho; Kim, Jinhye; Lee, Kwang Won; Seol, Geun Hee.

In: Journal of Pharmacy and Pharmacology, Vol. 71, No. 9, 01.01.2019, p. 1458-1468.

Research output: Contribution to journalArticle

@article{c5937ab4e04548c3af7a8c49da7b5b6c,
title = "Lancemaside A from Codonopsis lanceolata prevents hypertension by inhibiting NADPH oxidase 2-mediated MAPK signalling and improving NO bioavailability in rats",
abstract = "Objectives: This study investigated whether lancemaside A (LMA) can prevent hypertension and assessed the mechanisms of action of LMA in rats. Methods: Hypertension was induced by chronic immobilization stress and nicotine administration. Hypertensive vehicle rats were treated with LMA (1, 20, or 40 mg/kg) or nifedipine (10 mg/kg) as a positive control daily for 3 weeks. Key findings: In hypertensive vehicle rats, LMA dose-dependently reduced systolic blood pressure. LMA doses of 20 and 40 mg/kg reduced the aortic expression of nicotinamide adenine dinucleotide phosphate oxidase (NOX)2 (both P < 0.01), and 40 mg/kg LMA reduced serum malondialdehyde (P < 0.01). Serum nitrite levels were significantly higher in LMA treated rats than in hypertensive vehicle rats, with LMA doses of 20 and 40 mg/kg reducing the expression of endothelial nitric oxide synthase in rat aortas (P < 0.001 and P < 0.01, respectively). LMA also reduced the aortic levels of nuclear factor kappa B and the activation of the three isoforms of mitogen-activated protein kinase (MAPK). Conclusions: Lancemaside A prevents hypertension in rats by inhibiting the activation of MAPK signalling and the impairment in nitric oxide bioavailability due to NOX2-mediated oxidative stress. Thus, LMA may act as a preventive agent for hypertension.",
keywords = "antihypertension, lancemaside A, MAPK, NADPH oxidase, NO bioavailability",
author = "Shin, {You Kyoung} and Han, {A. Young} and Hsieh, {Yu Shan} and Soonho Kwon and Jinhye Kim and Lee, {Kwang Won} and Seol, {Geun Hee}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/jphp.13140",
language = "English",
volume = "71",
pages = "1458--1468",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",
number = "9",

}

TY - JOUR

T1 - Lancemaside A from Codonopsis lanceolata prevents hypertension by inhibiting NADPH oxidase 2-mediated MAPK signalling and improving NO bioavailability in rats

AU - Shin, You Kyoung

AU - Han, A. Young

AU - Hsieh, Yu Shan

AU - Kwon, Soonho

AU - Kim, Jinhye

AU - Lee, Kwang Won

AU - Seol, Geun Hee

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: This study investigated whether lancemaside A (LMA) can prevent hypertension and assessed the mechanisms of action of LMA in rats. Methods: Hypertension was induced by chronic immobilization stress and nicotine administration. Hypertensive vehicle rats were treated with LMA (1, 20, or 40 mg/kg) or nifedipine (10 mg/kg) as a positive control daily for 3 weeks. Key findings: In hypertensive vehicle rats, LMA dose-dependently reduced systolic blood pressure. LMA doses of 20 and 40 mg/kg reduced the aortic expression of nicotinamide adenine dinucleotide phosphate oxidase (NOX)2 (both P < 0.01), and 40 mg/kg LMA reduced serum malondialdehyde (P < 0.01). Serum nitrite levels were significantly higher in LMA treated rats than in hypertensive vehicle rats, with LMA doses of 20 and 40 mg/kg reducing the expression of endothelial nitric oxide synthase in rat aortas (P < 0.001 and P < 0.01, respectively). LMA also reduced the aortic levels of nuclear factor kappa B and the activation of the three isoforms of mitogen-activated protein kinase (MAPK). Conclusions: Lancemaside A prevents hypertension in rats by inhibiting the activation of MAPK signalling and the impairment in nitric oxide bioavailability due to NOX2-mediated oxidative stress. Thus, LMA may act as a preventive agent for hypertension.

AB - Objectives: This study investigated whether lancemaside A (LMA) can prevent hypertension and assessed the mechanisms of action of LMA in rats. Methods: Hypertension was induced by chronic immobilization stress and nicotine administration. Hypertensive vehicle rats were treated with LMA (1, 20, or 40 mg/kg) or nifedipine (10 mg/kg) as a positive control daily for 3 weeks. Key findings: In hypertensive vehicle rats, LMA dose-dependently reduced systolic blood pressure. LMA doses of 20 and 40 mg/kg reduced the aortic expression of nicotinamide adenine dinucleotide phosphate oxidase (NOX)2 (both P < 0.01), and 40 mg/kg LMA reduced serum malondialdehyde (P < 0.01). Serum nitrite levels were significantly higher in LMA treated rats than in hypertensive vehicle rats, with LMA doses of 20 and 40 mg/kg reducing the expression of endothelial nitric oxide synthase in rat aortas (P < 0.001 and P < 0.01, respectively). LMA also reduced the aortic levels of nuclear factor kappa B and the activation of the three isoforms of mitogen-activated protein kinase (MAPK). Conclusions: Lancemaside A prevents hypertension in rats by inhibiting the activation of MAPK signalling and the impairment in nitric oxide bioavailability due to NOX2-mediated oxidative stress. Thus, LMA may act as a preventive agent for hypertension.

KW - antihypertension

KW - lancemaside A

KW - MAPK

KW - NADPH oxidase

KW - NO bioavailability

UR - http://www.scopus.com/inward/record.url?scp=85070347093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070347093&partnerID=8YFLogxK

U2 - 10.1111/jphp.13140

DO - 10.1111/jphp.13140

M3 - Article

VL - 71

SP - 1458

EP - 1468

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 9

ER -